Abstract：
:Limited information is available on the relationship between expression of some additional aberrant phenotypic features and outcome of acute promyelocytic leukemia (APL) patients. Here, we set out to assess the frequency of CD15 and CD56 expression, and their prognostic value in a large series of APL patients. One hundred and fourteen adult patients consecutively diagnosed with PML/RARα-positive APL and homogeneously treated with the AIDA induction schedule at a single institution were included in the study. Twelve (10.5%) and 9 (8%) of the 114 patients expressed CD15 and CD56, respectively. CD15 expression identified a subset of patients with a classic morphologic subtype (92%), a prevalent association with a bcr1 expression (67%) with an unexpectedly higher frequency of relapses (42% vs 20% for the CD15- patients, p=0.03) and a low overall survival (OS) (median OS at 5 years 58% vs 85% for the CD15- patients, p=0.01). CD56 expression was detected only in patients with a classic morphologic subtype, a prevalent bcr3 expression (67%), high incidence of differentiation syndrome (55%), higher frequency of relapse (34% vs 20% for the CD56- population, p=0.04) and a low OS (60% vs 85% for the CD56- population p=0.02). We hereby confirm the negative prognostic value of CD56 and we show that the same applies also to cases expressing CD15. These aberrant markers may be considered for the refinement of risk-adapted therapeutic strategies in APL patients.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Breccia M,De Propris MS,Minotti C,Stefanizzi C,Raponi S,Colafigli G,Latagliata R,Guarini A,Foà Rdoi
10.1016/j.leukres.2013.11.008subject
Has Abstractpub_date
2014-02-01 00:00:00pages
194-7issue
2eissn
0145-2126issn
1873-5835pii
S0145-2126(13)00396-2journal_volume
38pub_type
杂志文章abstract：:We have previously reported that serum stem factor (SCF) levels are significantly lower in patients with myelodysplastic syndrome (MDS) than normal controls. We have now studied the effects of adding SCF to cultures of blood mononuclear cells from patients with MDS and normal subjects. Three of 17 patients with MDS sh...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(95)00034-l
更新日期：1995-08-01 00:00:00
abstract：PURPOSE:To study whether institutional clinical trial accrual volume affects clinical outcomes of younger (age less than 61 years) patients with acute myeloid leukemia. PATIENTS AND METHODS:We investigated the impact of clinical trial accrual on response rates, early mortality and survival in patients with AML enrolle...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2019.01.007
更新日期：2019-03-01 00:00:00
abstract：:Allogeneic hematopoietic stem cell transplantation provides curative therapy for some patients with advanced hematologic malignancies. Disease response after allogeneic transplant is, at least in part, mediated by donor immune cells. In this report we describe a cellular therapy using haploidentical peripheral blood s...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2008.05.015
更新日期：2008-12-01 00:00:00
abstract：:Ten patients with acute nonlymphocytic leukemia (ANLL) received bromodeoxyuridine (BrdU) at 100 mg/M2 intravenously over 1 h. BrdU is incorporated into the DNA by S-phase cells and was detected by using a monoclonal anti-BrdU antibody in the bone marrow aspirate (BM) and biopsy specimens obtained at the end of the inf...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(87)90160-3
更新日期：1987-01-01 00:00:00
abstract：:One of the major limitations of DNA flow cytometry (FCM) in hematologic malignancies is the lack of information about the proliferation activity of subpopulations of the heterogeneous bone marrow (BM) compartment. We studied the S-phase DNA content of immunophenotypically defined BM subpopulations (CD2+; CD19+; CD2/CD...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(91)90467-8
更新日期：1991-01-01 00:00:00
abstract：:Many elderly patients with newly diagnosed acute myeloid leukemia (AML) present with cardiac comorbidity precluding the use of anthracycline containing chemotherapy regimens. Amsacrine, a topoisomerase II inhibitor, has been proposed as possible alternative to anthracyclines. Here, we report about the combination of a...
journal_title：Leukemia research
pub_type： 临床试验,杂志文章
doi：10.1016/j.leukres.2007.06.015
更新日期：2008-03-01 00:00:00
abstract：:Oblimersen selectively targets Bcl-2 mRNA and has been shown to enhance the apoptotic activity of various antileukemic agents, including gemtuzumab ozogamicin (GO), in preclinical studies. We evaluated the efficacy and safety of oblimersen combined with GO in patients > or =60 years of age in first relapse with CD33+ ...
journal_title：Leukemia research
pub_type： 杂志文章,多中心研究
doi：10.1016/j.leukres.2005.10.025
更新日期：2006-07-01 00:00:00
abstract：:The effects of two recombinant human CSFs (G-CSF and GM-CSF) on the growth of blast progenitors from 36 acute myeloblastic leukemia patients were studied in methylcellulose and suspension cultures. Blast colony formation in methylcellulose and the growth of blast progenitors in suspension were stimulated by G-CSF or G...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(88)90063-x
更新日期：1988-01-01 00:00:00
abstract：:5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation and an active antileukemic agent, produced an induction of cytidine deaminase activity in human HL-60 myeloid leukemic cells. This increase in enzyme activity correlated with the induction of differentiation of the HL-60 leukemic cells as shown ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(90)90067-j
更新日期：1990-01-01 00:00:00
abstract：:HSP90 is a multi-client chaperone involved in regulating a large array of cellular processes and is commonly overexpressed in many different cancer types including hematological malignancies. Inhibition of HSP90 holds promise for targeting multiple molecular abnormalities and is therefore an attractive target for hete...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2015.03.016
更新日期：2015-06-01 00:00:00
abstract：:A double monoclonal component (MC) detected in the serum and/or urine represents a very rare occurrence (2-6% of monoclonal gammopathies). In this study, we report 34 patients with double serum MCs, focusing on the associated diseases. The diagnosis was made using high-resolution serum protein electrophoresis and immu...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2012.05.008
更新日期：2012-10-01 00:00:00
abstract：:Ectopic expression of LMO2 occurs in approximately 45% of T-lineage acute lymphoblastic leukemias (T-ALL), sometimes in association with chromosomal translocations. Recently, a lymphoproliferative disorder developed in two participants in a gene therapy trial due to LMO2 activation via integration of the retroviral ve...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2004.05.013
更新日期：2005-01-01 00:00:00
abstract：:Hybrid (C56BL/6 x DBA) (BDF1; H-2b/H-2d) mice bearing the P815 leukemia (H-2d) were grafted with a (CBA x C57BL/6)F1 (CBF1; H-2k/H-2b) cell suspension, comprising bone marrow cells (BMC; 25 x 10(6)/mouse) and spleen cells (SC; 55 x 10(6)/mouse) on day-4, then treated with cyclophosphamide (200 mg/kg) on day-2 and fina...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(97)00011-8
更新日期：1997-10-01 00:00:00
abstract：:We report the development and characterization of SJ-9A4, a monoclonal antibody (MoAb) produced against common acute lymphoblastic leukemia (C-ALL) cell lines. SJ-9A4 reacted with C-ALL, B-cell chronic lymphocytic leukemia (B-CLL), platelets and C-ALL neuroblastoma (NB) and the K562 cell lines. It had no significant r...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(83)90044-9
更新日期：1983-01-01 00:00:00
abstract：:The aim of this study is to detect the biologic and/or prognostic significance of survivin (S) and effector protease receptor 1: EPR-1 (E) expression in acute leukemias (34 ALL and 40 AML) by using RT-PCR. S and E expressions were found in 83.8 and 20.3% of the cases, respectively. S was detected in 90%, 76.5% and E w...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2007.01.005
更新日期：2007-11-01 00:00:00
abstract：:N-Propyl-N-nitrosourea (PNU) was proved to be a strong leukemogen, which induces myelogenous leukemia or thymic lymphoma in rats. BUF/Mna rats and F344 rats were the strain most susceptible to thymic lymphomagenic activity of PNU. In addition, F1 rats between BUF/Mna and WKY rats were also susceptible to PNU-lymphomag...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(88)90091-4
更新日期：1988-01-01 00:00:00
abstract：:The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis has been used to predict survival in diffuse large B-cell lymphoma (DLBCL) patients, but its prognostic significance with respect to different cell-of-origin (COO) subtypes remains unknown. We retrospectively analyzed 168 de novo DLBCL patients in th...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2014.03.013
更新日期：2014-06-01 00:00:00
abstract：:Despite the high effectiveness of various P-glycoprotein (P-gp) modulating substances in vitro their clinical value e.g. for combination treatment of acute myelogenous leukemias (AML) remains still unclear. This might be explainable by recent findings that other factors than P-gp (e.g. the multidrug resistance associa...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/s0145-2126(98)00192-1
更新日期：1999-05-01 00:00:00
abstract：BACKGROUND:For most cases of idiopathic acquired sideroblastic anemia (IASA), the molecular pathogenesis is unknown, despite the consistent morphological signature of abundant pathological ringed sideroblasts with their characteristic iron-engorged mitochondria. Moderately elevated free erythrocyte protoporphyrin (FEP)...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.06.005
更新日期：2007-05-01 00:00:00
abstract：:Expression of p14(ARF) and p16(INK4a) tumor suppressor genes was investigated in 109 patients with chronic myeloid leukemia (CML). The p14(ARF) and p16(INK4a) mRNA levels were significantly low in patients in chronic phase (CP) at presentation and high in patients treated with interferon-alpha (IFN-alpha), especially ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2006.02.002
更新日期：2006-10-01 00:00:00
abstract：:We investigated protracted low-dose oral Clofarabine for the treatment of myelodysplastic syndromes (MDS). Adults with an International Prognostic Scoring System (IPSS) score of INT-1 or higher who had failed first line therapy were eligible. INT-1 patients had to be transfusion-dependent. We started with oral Clofara...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2015.05.004
更新日期：2015-08-01 00:00:00
abstract：BACKGROUND:Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders, with very different prognosis in given individuals; age and comorbidities are emerging as relevant patient-related factors influencing clinical outcome in MDS. Our aim was to evaluate the impact of age, comorbidities and disease s...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2015.05.007
更新日期：2015-08-01 00:00:00
abstract：:The culture supernatants from 43 human cell lines obtained during log phase and from purified normal peripheral blood B-lymphocytes cultured at 10(6) cells ml-1 for 48 h in RPMI 1640-5% fetal calf serum were examined for interleukin-8 (IL-8) using Elisa kits. Constitutive IL-8 production was found for 14/15 B-cell lin...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(93)90164-g
更新日期：1993-12-01 00:00:00
abstract：:Thirty-nine patients with Philadelphia chromosome-positive (Ph1) chronic myelocytic leukemia (CML) were monitored using cytofluorometry and cytogenetics. During chronic phase, abnormal populations could be detected using commercially available monoclonal antibodies. Most of these abnormal populations had either an HLA...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(85)90097-9
更新日期：1985-01-01 00:00:00
abstract：:Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although several clinical characteristics can be associated with worse prognosis, more robust biological markers still remains uncovered. SMYD2, a member of SMYD protein family, regulates the activity of several proteins through methylation. I...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2014.01.013
更新日期：2014-04-01 00:00:00
abstract：:Most clinicians caring for patients with AML do not use the word "cure" casually, since for many patients diagnosed with AML, a state of cure or even of long term survival remains elusive. Analysis of prognostic factors may aid in defining the chance for cure in various AML subtypes, and improvements are required at a...
journal_title：Leukemia research
pub_type： 杂志文章,评审
doi：10.1016/j.leukres.2012.08.006
更新日期：2012-12-01 00:00:00
abstract：:miRNAs have been reported to be involved in the pathogenesis of many cancers. In this article, we investigated the role and the mechanisms of miR-15a/16 in the pathogenesis of multiple myeloma (MM). We found that miR-15a/16 was down-regulated in bone marrow-derived mononuclear cells (BM-MNCs) of newly diagnosed patien...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2016.08.013
更新日期：2016-10-01 00:00:00
abstract：:The tumor promoting agent TPA (phorbol ester; 1.6 X 10(-8)M) was used to induce the differentiation in vitro of B-chronic lymphocytic leukemia (B-CLL) cells from 14 untreated patients. The uninduced phenotype was SIg+, Mrbc+, RFT-1+, RFA-4-, FMC7-. After 72 h incubation with TPA, B-CLL cells became RFA-4+, FMC7+ and l...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(84)90005-5
更新日期：1984-01-01 00:00:00
abstract：:Replication of the Friend spleen focus forming virus (SFFV) in C3H/HeJ or C57BL/6J mouse continuous bone marrow cultures is associated with an increased cumulative production of pluripotential/hematopoietic stem cells (CFUs), granulocyte-macrophage progenitor cells (GM-CFUc), and total granulocytes, compared to uninfe...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/0145-2126(83)90133-9
更新日期：1983-01-01 00:00:00
abstract：:Activating mutations of the c-kit gene are frequently found in CBF (core binding factor) leukemias. We evaluated the effect of tyrosine kinase inhibitor dasatinib in leukemic cell lines bearing or not c-kit mutations. Our data demonstrate that in the AML Kasumi-1 cell line, bearing the N822K c-kit mutation, dasatinib ...
journal_title：Leukemia research
pub_type： 杂志文章
doi：10.1016/j.leukres.2012.10.011
更新日期：2013-02-01 00:00:00
